drugset / Trial / NCT00117052

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

NCT00117052

Phase 3 Completed 673 enrolled Amgen
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.

Timeline

Start
2004-09
Primary completion
2005-11
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cinacalcet Other / unclassified Oral